Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Wall St set for best week since April as payrolls surprise eases rate-hike jitters
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on US jobs report, worries over peace talks
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Nurix (NRIX) PT Raised to $34 at Stifel
October 14, 2024 8:33 AM EDT(Updated - October 14, 2024 8:34 AM EDT)
Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst commented: "We like implied risk/reward into the anticipated update of P1/1b NX-5948 data... More
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
October 14, 2024 7:36 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX reported 3Q24 earnings and provided a pipeline update. Most importantly, development of NX-5948 remains on track with two Phase Ia updates expected... More
Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
October 14, 2024 3:50 AM EDTNurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.
For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.
... MoreJefferies Starts Nurix (NRIX) at Buy
October 11, 2024 5:25 AM EDTJefferies analyst Roger Song initiates coverage on Nurix (NASDAQ: NRIX) with a Buy rating and a price target of $41.00.
The analyst said: "NRIX focuses on targeted protein modulation for cancer and I&I. Lead '5948 (BTK degrader) aims to better address broad BTK... More
